PDL BioPharma Inc (NASDAQ:PDLI) had declared a cash dividend of $0.0500 on Jun 13, 2016. The shares will quote ex-dividend on Jun 2, 2016 and the record date has been fixed for Jun 6, 2016. On Jun 13, 2016 share price, the yield comes out to be 6.5359%. The dividend payable date has been fixed on Jun 13, 2016.
PDL BioPharma Inc (PDLI) shares turned negative on Fridays trading session with the shares closing down -0.03 points or -0.96% at a volume of 19,96,174. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $3.18. The peak price level was also seen at $3.18 while the days lowest was $3.07. Finally the shares closed at $3.09. The 52-week high of the shares is $6.75 while the 52-week low is $2.58. According to the latest information available, the market cap of the company is $510 M.
PDL BioPharma Inc(PDLI) last announced its earnings results on May 4, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $130.23M. Analysts had an estimated revenue of $142.05M. Earnings per share were $0.52. Analysts had estimated an EPS of $0.50.
Several Insider Transactions has been reported to the SEC. On Dec 16, 2015, Peter S Garcia (CFO) purchased 15,000 shares at $3.53 per share price.Also, On Dec 7, 2015, Steffen Pietzke (Controller and CAO) purchased 20,590 shares at $3.64 per share price.
PDL BioPharma Inc. manages a portfolio of patents and royalty assets consisting of its Queen et al. patents license agreements with various biotechnology and pharmaceutical companies and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies academic institutions and inventors. It is focused on intellectual property asset management acquiring new income generating assets and maximizing value for its stockholders. The Company receives royalties on a number of marketed products that use its technology and it has liscensed a number of humanized antibody products in late-stage clinical trials. As of December 31 2014 the Company received royalties on sales of the ten humanized antibody products which include Avastin Herceptin Xolair Lucentis Perjeta Kadcyla Tysabri Actemra Gazyva and Entyvio.